**Supplementary Table 2. Stepwise diagnostic algorithm to determine advanced fibrosis in NAFLD patients.**

**A. MetDis-LSM**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Metabolic disorders\*** | **None** | **RH or FPG** | | | **RH & FPG** |
| LSM in kPa | <7.9 | 7.9-9.6 | >9.6 |
| F0-2 | 63 | 41 | 23 | 37 | 40 |
| F3-4 | 3 | 3 | 2 | 9 | 19 |

**B. LSM-MetDis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **LSM in kPa** | **<7.9** | **7.9-9.6** | | | **>9.6** |
| Metabolic disorders\* | None | RH or FPG | RH & FPG |
| F0-2 | 99 | 10 | 23 | 4 | 62 |
| F3-4 | 4 | 1 | 2 | 3 | 26 |

**C. MetDis-NFS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Metabolic disorders\*** | **None** | **RH or FPG** | | | **RH & FPG** |
| NAFLD fibrosis score | <-1.455 | -1.455-0.676 | >0.676 |
| F0-2 | 63 | 90 | 15 | 0 | 40 |
| F3-4 | 3 | 8 | 8 | 0 | 19 |

**D. NFS-MetDis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **NAFLD fibrosis score** | **<-1.455** | **-1.455-0.676** | | | **>0.676** |
| Metabolic disorders\* | None | RH or FPG | RH & FPG |
| F0-2 | 166 | 4 | 15 | 20 | 1 |
| F3-4 | 18 | 0 | 8 | 10 | 2 |

**E. MetDis-FIB-4**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Metabolic disorders\*** | **None** | **RH or FPG** | | | **RH & FPG** |
| FIB-4 | <1.30 | 1.30-3.25 | >3.25 |
| F0-2 | 63 | 70 | 33 | 2 | 40 |
| F3-4 | 3 | 4 | 9 | 3 | 19 |

**F. FIB-4-MetDis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **FIB-4** | **<1.30** | **1.30-3.25** | | | **>3.25** |
| Metabolic disorders\* | None | RH or FPG | RH & FPG |
| F0-2 | 136 | 15 | 33 | 18 | 5 |
| F3-4 | 13 | 0 | 9 | 13 | 3 |

\*RH, reduced high-density lipoprotein cholesterol or on Rx; FPG, more than 5.6 mmol/L or diabetes, according to the guideline of metabolic syndrome, 2005.

**Supplementary information**

Qualified researchers may request access to patient-level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient-level data will be anonymized and study documents will be redacted to protect the privacy of our trial participants. Further details on Sanofi’s data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/.